Filtered By:
Cancer: Breast Cancer
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 60669 results found since Jan 2013.
Breast Cancer Risk Reduction: Current Status and Emerging Trends to Increase Efficacy and Reduce Toxicity of Preventive Medication
Surg Oncol Clin N Am. 2023 Oct;32(4):631-646. doi: 10.1016/j.soc.2023.05.001. Epub 2023 Jun 15.ABSTRACTThe primary prevention of breast cancer is a worthwhile goal for which the efficacy of antiestrogens is well established. However, implementation has been problematic related to low prioritization by providers and the reluctance of high-risk women to experience medication side effects. Emerging solutions include improved risk estimation through the use of polygenic risk scores and the application of radiomics to screening mammograms; and optimization of medication dose to limit toxicity. The identification of agents to pr...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Seema Ahsan Khan Source Type: research
Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
CONCLUSION: To generate nomograms that predicted DFS and OS, independent predictors of DFS in ER-positive/HER2-negative breast cancer patients were chosen. The nomograms successfully stratified patients into prognostic categories and worked well in both internal validation and external validation.PMID:37713046 | DOI:10.1007/s12094-023-03316-0
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Xinming Song Pintian Wang Ruiling Feng Mandika Chetry E Li Xiaohua Wu Zewa Liu Shasha Liao Jing Lin Source Type: research
Machine learning- and WGCNA-mediated double analysis based on genes associated with disulfidptosis, cuproptosis and ferroptosis for the construction and validation of the prognostic model for breast cancer
CONCLUSION: Multiplex analysis based on DRGs, CRGs and FRGs correlated strongly with BC, providing new insights for developing clinical prognostic tools and designing immunotherapy regimens for BC patients.PMID:37712959 | DOI:10.1007/s00432-023-05378-7
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Lijun Xu Shanshan Wang Dan Zhang Yunxi Wu Jiali Shan Huixia Zhu Chongyu Wang Qingqing Wang Source Type: research
The value of radiomics model based on ultrasound image features in the differentiation between minimal breast cancer and small benign breast masses
CONCLUSION: The radiomics model based on ultrasound image features has a satisfied predictive ability for small breast masses, and is expected to become a potential tool for the diagnosis of MBC, and it is a zero cost (in terms of patient participation and imaging time).PMID:37712556 | DOI:10.1002/jcu.23556
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Shuyi Lyu Meiwu Zhang Baisong Zhang Jiazhen Zhu Libo Gao Yuqin Qiu Liu Yang Yan Zhang Source Type: research
Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response
J Clin Invest. 2023 Sep 15;133(18):e172156. doi: 10.1172/JCI172156.ABSTRACTAntibody-drug conjugates (ADCs) have emerged as a revolutionary therapeutic class, combining the precise targeting ability of monoclonal antibodies with the potent cytotoxic effects of chemotherapeutics. Notably, ADCs have rapidly advanced in the field of breast cancer treatment. This innovative approach holds promise for strengthening the immune system through antibody-mediated cellular toxicity, tumor-specific immunity, and adaptive immune responses. However, the development of upfront and acquired resistance poses substantial challenges in maximi...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Hannah L Chang Blake Schwettmann Heather L McArthur Isaac S Chan Source Type: research
Correction: Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway
J Exp Clin Cancer Res. 2023 Sep 16;42(1):241. doi: 10.1186/s13046-023-02818-7.NO ABSTRACTPMID:37715266 | PMC:PMC10504694 | DOI:10.1186/s13046-023-02818-7
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Yulin Peng Yan Wang Ning Tang Dongdong Sun Yulong Lan Zhenlong Yu Xinyu Zhao Lei Feng Baojing Zhang Lingling Jin Fabiao Yu Xiaochi Ma Chuanzhu Lv Source Type: research
Low interobserver agreement among subspecialised breast pathologists in evaluating HER2-low breast cancer
CONCLUSIONS: Subspecialised breast pathologists have suboptimal agreement for immunohistochemical evaluation of HLBC using the modified Ki-67 methodology. An urgent need remains for a new assay/algorithm to reliably evaluate HLBC.PMID:37714693 | DOI:10.1136/jcp-2023-209055
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Gulisa Turashvili Yuan Gao Di Andy Ai Abdulwahab M Ewaz Sandra Gjorgova Gjeorgjievski Qun Wang Thi T A Nguyen Chao Zhang Xiaoxian Li Source Type: research
Personalizing Breast Cancer Care
Surg Oncol Clin N Am. 2023 Oct;32(4):xv-xvi. doi: 10.1016/j.soc.2023.06.001. Epub 2023 Jun 21.NO ABSTRACTPMID:37714647 | DOI:10.1016/j.soc.2023.06.001
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Melissa Pilewskie Source Type: research
Lasting Impacts of the COVID-19 Pandemic on Breast Cancer Diagnosis and Treatment in the United States
Surg Oncol Clin N Am. 2023 Oct;32(4):811-819. doi: 10.1016/j.soc.2023.05.010. Epub 2023 May 10.ABSTRACTThe COVID-19 pandemic was an unprecedented time that placed unique challenges on the screening and treatment of breast cancer in the United States. Collaboration among medical disciplines and societies provided guidelines and strategies to mitigate the exposure of patients and medical providers to the virus and provide optimal care. We discuss the changes that the pandemic had on the multidisciplinary management of breast cancer.PMID:37714645 | PMC:PMC10169575 | DOI:10.1016/j.soc.2023.05.010
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Jenna L Sturz Judy C Boughey Source Type: research
Addressing Inequalities in Breast Cancer Care Delivery
Surg Oncol Clin N Am. 2023 Oct;32(4):799-810. doi: 10.1016/j.soc.2023.05.009. Epub 2023 Jun 16.ABSTRACTBreast cancer treatment, timeliness of care, and clinical outcomes are inferior for patients of Black race and Hispanic ethnicity, and the origin of these inequities is multifactorial. Owing to aggregate reporting of data in the United States for patients of Asian, Native Hawaiian, and Pacific Islander ancestry, disparities within and across these groups are difficult to appreciate. In large part due to low prevalence, male breast cancer remains understudied, and treatment algorithms are primarily extrapolated from resear...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Leisha C Elmore Oluwadamilola M Fayanju Source Type: research
Incorporating Value-Based Decisions in Breast Cancer Treatment Algorithms
Surg Oncol Clin N Am. 2023 Oct;32(4):777-797. doi: 10.1016/j.soc.2023.05.008. Epub 2023 Jun 9.ABSTRACTGiven the excellent prognosis and availability of evidence-based treatment, patients with early-stage breast cancer are at risk of overtreatment. In this review, we summarize key opportunities to incorporate value-based decisions to optimize the delivery of high-value treatment across the breast cancer care continuum.PMID:37714643 | DOI:10.1016/j.soc.2023.05.008
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Ton Wang Lesly A Dossett Source Type: research
Fertility and Sexual Health in Young Women with Early-Stage Breast Cancer
Surg Oncol Clin N Am. 2023 Oct;32(4):747-759. doi: 10.1016/j.soc.2023.05.012. Epub 2023 Jun 15.ABSTRACTFertility and sexual health may be impaired by early breast cancer treatment in young women, and these issues should be addressed at diagnosis and through survivorship. Future fertility interest and risk should be considered and communicated, and early referral made to an infertility specialist for those interested. Data regarding safety of fertility preservation options as well as pregnancy after breast cancer are overall reassuring. Patients should be counseled about the impact of systemic therapies and breast surgeries...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Marla Lipsyc-Sharf Ann H Partridge Source Type: research
Selecting Triple Negative Breast Cancer Patients for Immunotherapy
Surg Oncol Clin N Am. 2023 Oct;32(4):733-745. doi: 10.1016/j.soc.2023.05.005. Epub 2023 Jun 5.ABSTRACTThe approval of preoperative immunotherapy combined with chemotherapy is a practice-changing advance for patients with early-stage triple-negative breast cancer. The optimal patient selection requires careful attention to staging and balancing potential risks with expected benefits, particularly as it relates to immune-related adverse events.PMID:37714640 | DOI:10.1016/j.soc.2023.05.005
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Stephanie Downs-Canner Elizabeth A Mittendorf Source Type: research
Incorporating Tumor Biology to Select Patients for the Omission of Radiation Therapy
Surg Oncol Clin N Am. 2023 Oct;32(4):725-732. doi: 10.1016/j.soc.2023.05.006. Epub 2023 Jun 9.ABSTRACTAlthough adjuvant breast radiotherapy has long been a universal component of breast conservation therapy (BCT), it is now clear that "breast cancer" is a broad class of many disparate diseases with varying natural histories and risk profiles. In turn, some breast conservation patients enjoy exceedingly favorable outcomes following surgery alone. Ongoing trials seek to identify such low-risk patient populations, hypothesizing that some may safely forego radiotherapy. Whereas prior-generation trials focused on clinicopatholo...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Lior Z Braunstein Source Type: research
